60 related articles for article (PubMed ID: 23410005)
1. Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
Morales GA; Garlich JR; Su J; Peng X; Newblom J; Weber K; Durden DL
J Med Chem; 2013 Mar; 56(5):1922-39. PubMed ID: 23410005
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
[TBL] [Abstract][Full Text] [Related]
3. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
4. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Garlich JR; De P; Dey N; Su JD; Peng X; Miller A; Murali R; Lu Y; Mills GB; Kundra V; Shu HK; Peng Q; Durden DL
Cancer Res; 2008 Jan; 68(1):206-15. PubMed ID: 18172313
[TBL] [Abstract][Full Text] [Related]
5. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kaizawa H; Moritomo H; Koizumi T; Ohishi T; Okada M; Ohta M; Tsukamoto S; Parker P; Workman P; Waterfield M
Bioorg Med Chem; 2006 Oct; 14(20):6847-58. PubMed ID: 16837202
[TBL] [Abstract][Full Text] [Related]
7. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.
Baiz D; Pinder TA; Hassan S; Karpova Y; Salsbury F; Welker ME; Kulik G
J Med Chem; 2012 Sep; 55(18):8038-46. PubMed ID: 22924393
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation.
Giordanetto F; Wållberg A; Cassel J; Ghosal S; Kossenjans M; Yuan ZQ; Wang X; Liang L
Bioorg Med Chem Lett; 2012 Nov; 22(21):6665-70. PubMed ID: 23010274
[TBL] [Abstract][Full Text] [Related]
10. Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
Wang J; Wang X; Chen Y; Chen S; Chen G; Tong L; Meng L; Xie Y; Ding J; Yang C
Bioorg Med Chem Lett; 2012 Jan; 22(1):339-42. PubMed ID: 22130133
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.
Hardcastle IR; Cockcroft X; Curtin NJ; El-Murr MD; Leahy JJ; Stockley M; Golding BT; Rigoreau L; Richardson C; Smith GC; Griffin RJ
J Med Chem; 2005 Dec; 48(24):7829-46. PubMed ID: 16302822
[TBL] [Abstract][Full Text] [Related]
12. Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines.
Lu XY; Ciraolo E; Stefenia R; Chen GQ; Zhang Y; Hirsch E
Appl Microbiol Biotechnol; 2011 Mar; 89(5):1423-33. PubMed ID: 21286711
[TBL] [Abstract][Full Text] [Related]
13. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
14. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
15. Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3Kα: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives.
Yin Y; Wu X; Han HW; Sha S; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
Org Biomol Chem; 2014 Dec; 12(45):9157-65. PubMed ID: 25296388
[TBL] [Abstract][Full Text] [Related]
16. Chroman-4-one- and chromone-based sirtuin 2 inhibitors with antiproliferative properties in cancer cells.
Seifert T; Malo M; Kokkola T; Engen K; Fridén-Saxin M; Wallén EA; Lahtela-Kakkonen M; Jarho EM; Luthman K
J Med Chem; 2014 Dec; 57(23):9870-88. PubMed ID: 25383691
[TBL] [Abstract][Full Text] [Related]
17. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines.
Morrison R; Al-Rawi JM; Jennings IG; Thompson PE; Angove MJ
Eur J Med Chem; 2016 Mar; 110():326-39. PubMed ID: 26854431
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors.
Kendall JD; Rewcastle GW; Frederick R; Mawson C; Denny WA; Marshall ES; Baguley BC; Chaussade C; Jackson SP; Shepherd PR
Bioorg Med Chem; 2007 Dec; 15(24):7677-87. PubMed ID: 17869522
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Kong D; Yamori T
Cancer Sci; 2008 Sep; 99(9):1734-40. PubMed ID: 18616528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
